Nexalin Technology (Nasdaq: NXL) has received USPTO patent approval for its Deep Intracranial Frequency Stimulation (DIFS™) technology, specifically for treating Substance Use Disorders (SUDs). The patent, titled 'Alternating Current Dynamic Frequency Stimulation Method for Opioid Use Disorder (OUD) and Substance Use Disorder (SUD),' strengthens the company's intellectual property portfolio.
DIFS™ is a non-invasive, drug-free treatment designed to help individuals with various substance use disorders, including opioid, alcohol, and stimulant addictions. The technology works by applying deep-brain stimulation at dynamic frequencies to regulate neural pathways associated with addiction and withdrawal symptoms.
The technology aims to address chronic relapse by targeting underlying anxiety, depression, and cravings through neuromodulation, potentially offering an alternative to traditional treatments like medication-assisted therapy (MAT) that may have accessibility issues and side effects.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.